CCL11 as a New Therapeutic Target for Colitis and Colon Cancer
Congressional District Code:
Biomedical Laboratory R&D
July 2019 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
With more than 1.6 million Americans affected, inflammatory bowel disease (IBD) causes significant morbidity and can progress to colon cancer. There are two main forms of IBD: ulcerative colitis (UC) and Crohn's disease, and the associated abnormal immune response continues to be investigated with the goal of discovering new therapeutics or avenues for intervention. We have previously shown that in a prospectively collected cohort of adult UC patients, CCL11 (also called eotaxin-1), a chemoattra...